Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Antiepileptic — Second-Line Status Epilepticus

Levetiracetam IV (Status Epilepticus)

Brand names: Keppra IV

This is intravenous levetiracetam used as a second-line agent in established convulsive status epilepticus (after first-line benzodiazepines), given as a short infusion.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Levetiracetam binds the synaptic vesicle protein SV2A, modulating neurotransmitter release to reduce seizure activity — a mechanism distinct from sodium-channel and GABAergic antiepileptics.

Prescribing in practice

  • It is favoured in status epilepticus because it needs no cardiac or blood-pressure monitoring and has few interactions (unlike phenytoin) — but reduce the dose in renal impairment.
  • It is one of several comparable second-line options (with phenytoin/fosphenytoin and sodium valproate); the choice depends on patient factors and local protocol.
  • Behavioural and mood effects (agitation, irritability, low mood) can occur, particularly with continued oral use.

Monitoring

Monitor seizure response and conscious level acutely; with ongoing treatment review renal function and mood/behaviour.

Counselling the patient

  • It is given by infusion in hospital to stop a prolonged seizure; treatment is usually switched to tablets once the patient is stable.
  • Report low mood or marked irritability when it is continued as regular treatment.

Evidence & guidelines

Comparable to phenytoin and valproate as second-line therapy in established status epilepticus (ESETT in adults; EcLiPSE/ConSEPT in children; NICE NG217).

Reference: STELUS Trial; ESETT Trial (NEJM 2019); NICE NG217; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways